Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

pamidronate

pamidronate
  • Formulary Bisphosphonate Formulary
  • Restricted Pamidronate and Zometa are formulary status, restricted, to be used by: oncology, nephrology, pneumatology, endocrinology.
  • Restricted Pamidronate --> Restricted to
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Aredia POWDER FOR INJECTION, INTRAVENOUS 30 mg, 90 mg    
Aredia SOLUTION, INTRAVENOUS 3 mg/mL, 9 mg/mL    
VIEW MORE Miscellaneous Therapeutic Agents
CLASS
920000
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

pamidronate (Aredia)

  • 90 mg; infuse over 2 hours.

zoledronic acid (Zometa)

  • 4 mg

 

Pamidronate is restricted to "no substitution" orders, otherwise interchange to zoledronic acid (Zometa) at a dose ratio of pamidronate 90 mg = Zoledronic acid 4 mg.

Reviewed: October 22, 2019

Last updated: Jun. 28, 2022






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved